Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Effects of HIV Pre-Exposure Prophylaxis (PrEP) on Cardiovascular-Kidney-Metabolic Health and Risk for Cardiovascular Disease

Award Number: R01HL178400
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/05/2025
PERIOD OF PERFORMANCE END DATE: 06/30/2029

Group Awards By:

View Award Description

Effects of HIV Pre-Exposure Prophylaxis (PrEP) on Cardiovascular-Kidney-Metabolic Health and Risk for Cardiovascular Disease - PROJECT ABSTRACT Tenofovir-containing antiretroviral therapy has been associated with increased risk for metabolic conditions and cardiovascular disease (CVD) among persons with HIV; yet it is less clear if chronic use of tenofovir-based HIV pre-exposure prophylaxis (PrEP) may affect risk for these conditions in individuals without HIV. Evidence from PrEP clinical trials and limited observational studies suggests that the use of emtricitabine/tenofovir disoproxil fumarate (TDF) and emtricitabine/tenofovir alafenamide (TAF) for HIV PrEP may affect CVD risk through changes in metabolic profile and kidney dysfunction. Through the efforts of the U.S. Ending the HIV Epidemic Initiative (EHE), oral PrEP use, especially generic TDF, is likely to increase significantly and expand to include individuals at substantial risk for HIV who are older and with more comorbidities. Existing PrEP trials and open-label studies of younger populations with short follow-up were not designed to evaluate long-term CVD risk, and findings have limited generalizability due to relatively lower number of persons of color among trial participants. Considering the interplay among metabolic risk factors, chronic kidney disease, and the cardiovascular system, it is critical to evaluate effects of PrEP on cardiovascular-kidney-metabolic (CKM) health among diverse populations. However, no cohort exists to comprehensively evaluate both metabolic and renal outcomes and clinical management and control of metabolic risk factors over time in clinical care settings. We propose to use electronic health record data from 3 integrated health care systems in California and Mid-Atlantic States (Maryland, District of Columbia, Virginia) to conduct a longitudinal cohort study of diverse PrEP candidates with or without initiation of oral PrEP during 2012-2024. We will estimate observational analogues of both intention-to-treat effect and per-protocol effect of PrEP use on CKM health, risk of clinical CVD events, and all-cause mortality. We will also evaluate the differences in treatment initiation and control of metabolic risk factors. We will use a novel sex-specific and race-free risk calculator that combines measures of cardiovascular, kidney and metabolic health to predict 10- and 30-year risk for total CVD, atherosclerotic CVD, and heart failure. Specific Aims are: 1) to examine associations between PrEP use and incident CKM conditions; 2) to assess differences in treatment initiation and control of metabolic risk factors among PrEP users compared with non-users without HIV; 3) to examine associations between PrEP use and risk of cardiovascular events (primary outcome) and all-cause mortality (secondary outcome) in individuals aged 30-79 years with no prior history of CVD. This study aligns with, and advances, the national priorities to elucidate the impact of PrEP on heart, lung, blood, and sleep conditions (NOT-HL-21-025), and will generate much-needed empirical evidence to inform guidelines for prescribing PrEP and help develop tailored prevention strategies to reduce cardiovascular morbidity and mortality among individuals taking PrEP.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $730,229 )
2026	2026	KAISER FOUNDATION HOSPITALS	1800 HARRISON ST FL 16	OAKLAND	CA	94612	ALAMEDA	USA	Cardiovascular Diseases Research	000	2	8/4/2026	NON-COMPETING CONTINUATION	$730,229
														Subtotal = $730,229

Issue Date FY: 2025 ( Subtotal = $743,492 )
2025	2025	KAISER FOUNDATION HOSPITALS	1800 HARRISON ST FL 16	OAKLAND	CA	94612	ALAMEDA	USA	Cardiovascular Diseases Research	000	1	9/8/2025	NEW	$743,492
														Subtotal = $743,492

Grand Total All Awards = $1,473,721

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Effects of HIV Pre-Exposure Prophylaxis (PrEP) on Cardiovascular-Kidney-Metabolic Health and Risk for Cardiovascular Disease

Award Number: R01HL178400

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/05/2025

PERIOD OF PERFORMANCE END DATE: 06/30/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer